Overview

This trial is active, not recruiting.

Condition neuroblastoma
Treatments topotecan hydrochloride, autologous hematopoietic stem cell transplantation, iobenguane i 131, total-body irradiation
Phase phase 2
Sponsor Centre Oscar Lambret
Collaborator National Cancer Institute, France
Start date November 2008
End date July 2016
Trial size 30 participants
Trial identifier NCT00960739, MIITOP-0607

Summary

RATIONALE: Radioactive drugs, such as iodobenzylguanidine meta-I131, may carry radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A stem cell transplant may be able to replace the cells that were destroyed by iodobenzylguanidine meta-i131 and topotecan hydrochloride.

PURPOSE: This phase II trial is studying the side effects of iodobenzylguanidine meta-I131 given together with topotecan hydrochloride and to see how well it works in treating young patients with refractory or relapsed metastatic neuroblastoma.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). * Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. * A dosimetry is performed during hospitalization. A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. * Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG. If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled.
topotecan hydrochloride Topotecan
The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
autologous hematopoietic stem cell transplantation hematopoietic stem cell transplantation
Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
iobenguane i 131
444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
total-body irradiation
the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)

Primary Outcomes

Measure
Response rate
time frame: Up to 12 months

Secondary Outcomes

Measure
Toxicity
time frame: Up to 30 days after study treatment

Eligibility Criteria

Male or female participants from 1 year up to 20 years old.

Inclusion criteria: - Histologically confirmed neuroblastoma - Metastatic disease that is recurrent or refractory to induction therapy - Primary or metastatic tumor target with MIBG fixation (tumor/soft tissue) > 2 - Autologous bone marrow or peripheral blood stem cells must be available - WHO performance status (PS) 0-1 OR Lansky PS 70-100% - Life expectancy > 2 months - ANC ≥ 1,000/mm³ - Platelet count ≥ 100,000/mm³ - Creatinine clearance normal for age - Not pregnant or nursing - Fertile patients must use effective contraception - No prior hypersensitivity to topotecan or its excipients - No toxicity to other organs ≥ NCI-CTCAE v3.0 grade 2 - No other debilitating disease - No HIV positivity - More than 30 days since prior external-beam radiation (6 weeks if cranio-spinal, abdominal, or pulmonary) - At least 3 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas) - No other contraindicated biologic therapy that cannot be discontinued for ≥ 4 courses during MIBG therapy Exclusion criteria: - Pregnancy or breastfeeding women - HIV positive - Participation to another phase I,II or III clinical trial - Other invalidating pathology - Concomitant treatment interfering with MIBG - Hypersensibility to Topotecan

Additional Information

Official title Phase II Study of the Association of Iodobenzylguanidine Meta-I131 (I131 MIBG) and Topotecan in the Treatment of Refractory or Relapsed Metastatic Neuroblastoma
Principal investigator Anne Sophie Defachelles, MD
Description OBJECTIVES: Primary - Determine the antitumor activity of iodobenzylguanidine meta-I131 (^131I-MIBG) and topotecan in young patients with refractory or relapsed metastatic neuroblastoma. Secondary - Determine the hematological and extra-hematological toxicities of this regimen. OUTLINE: This is a multicenter study. During the 21 days before treatment begins, autologous peripheral blood stem cells (PBSC) are collected. Patients receive topotecan hydrochloride IV over 30 minutes daily on days 1-5 and iodobenzylguanidine meta-^131I IV over 2 hours on day 1. Treatment repeats every 21 days for 2 courses. Patients also undergo total-body irradiation. On day 10 of the second course, autologous PBSC are reinfused. After completion of study therapy, patients are followed at 6 and 12 months.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Centre Oscar Lambret.